Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.365 USD | -2.07% | -0.21% | +84.77% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 155M 12.93B |
---|---|---|---|---|---|
Net income 2024 * | -34M -2.84B | Net income 2025 * | -48M -4.01B | EV / Sales 2024 * | - |
Net cash position 2024 * | 80.2M 6.7B | Net cash position 2025 * | 40.65M 3.39B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.84
x | P/E ratio 2025 * |
-3.17
x | Employees | 28 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.99% |
Latest transcript on Regulus Therapeutics Inc.
1 day | -2.07% | ||
1 week | -0.21% | ||
Current month | +3.28% | ||
1 month | +7.01% | ||
3 months | +0.21% | ||
6 months | +75.19% | ||
Current year | +84.77% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Hagan
CEO | Chief Executive Officer | 55 | 04/16/04 |
Preston Klassen
PSD | President | 55 | 22/23/22 |
Crispina Calsada
DFI | Director of Finance/CFO | 54 | 30/19/30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 57 | 01/17/01 |
David Baltimore
BRD | Director/Board Member | 86 | 01/09/01 |
Director/Board Member | 75 | 01/13/01 |
Date | Price | Change | Volume |
---|---|---|---|
12/24/12 | 2.365 | -2.07% | 425,966 |
11/24/11 | 2.415 | -1.43% | 430,434 |
10/24/10 | 2.45 | +9.87% | 762,627 |
07/24/07 | 2.23 | 0.00% | 209,601 |
06/24/06 | 2.23 | -5.91% | 311,366 |
Delayed Quote Nasdaq, June 13, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+84.77% | 155M | |
+16.93% | 123B | |
+17.01% | 111B | |
-7.23% | 23.63B | |
+3.00% | 22.58B | |
-14.29% | 17.26B | |
-6.79% | 17.6B | |
-37.63% | 17.61B | |
+2.17% | 13.55B | |
+24.42% | 11.34B |
- Stock Market
- Equities
- RGLS Stock